ESR1 and breast carcinoma: Also, there are data that imply that, both in humans and mice, IL-33/ST2 signaling in breast carcinoma could induce stemness of a malignant cell, making it more challenging to treat with classic therapeutics, such as estrogen receptor inhibitors [58].